• Find People
  • Campus Map
  • PiratePort
  • A-Z
    • About
    • Submit
    • Browse
    • Login
    View Item 
    •   ScholarShip Home
    • Other Campus Research
    • Open Access
    • View Item
    •   ScholarShip Home
    • Other Campus Research
    • Open Access
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of The ScholarShipCommunities & CollectionsDateAuthorsTitlesSubjectsTypeDate SubmittedThis CollectionDateAuthorsTitlesSubjectsTypeDate Submitted

    My Account

    Login

    Statistics

    View Google Analytics Statistics

    Rho GTPases as therapeutic targets in Alzheimer’s disease

    Thumbnail
    View/ Open
    10.1186-s13195-017-0320-4.pdf (575.6Kb)

    Show full item record
    Author
    Aguilar, Byron J.; Zhu, Yi; Lu, Qun
    Abstract
    The progress we have made in understanding Alzheimer’s disease (AD) pathogenesis has led to the identification of several novel pathways and potential therapeutic targets. Rho GTPases have been implicated as critical components in AD pathogenesis, but their various functions and interactions make understanding their complex signaling challenging to study. Recent advancements in both the field of AD and Rho GTPase drug development provide novel tools for the elucidation of Rho GTPases as a viable target for AD. Herein, we summarize the fluctuating activity of Rho GTPases in various stages of AD pathogenesis and in several in vitro and in vivo AD models. We also review the current pharmacological tools such as NSAIDs, RhoA/ROCK, Rac1, and Cdc42 inhibitors used to target Rho GTPases and their use in AD-related studies. Finally, we summarize the behavioral modifications following Rho GTPase modulation in several AD mouse models. As key regulators of several AD-related signals, Rho GTPases have been studied as targets in AD. However, a consensus has yet to be reached regarding the stage at which targeting Rho GTPases would be the most beneficial. The studies discussed herein emphasize the critical role of Rho GTPases and the benefits of their modulation in AD.
    URI
    http://hdl.handle.net/10342/8387
    Date
    2017-12-15
    Citation:
    APA:
    Aguilar, Byron J., & Zhu, Yi, & Lu, Qun. (December 2017). Rho GTPases as therapeutic targets in Alzheimer’s disease. , (), - . Retrieved from http://hdl.handle.net/10342/8387

    Display/Hide MLA, Chicago and APA citation formats.

    MLA:
    Aguilar, Byron J., and Zhu, Yi, and Lu, Qun. "Rho GTPases as therapeutic targets in Alzheimer’s disease". . . (), December 2017. September 29, 2023. http://hdl.handle.net/10342/8387.
    Chicago:
    Aguilar, Byron J. and Zhu, Yi and Lu, Qun, "Rho GTPases as therapeutic targets in Alzheimer’s disease," , no. (December 2017), http://hdl.handle.net/10342/8387 (accessed September 29, 2023).
    AMA:
    Aguilar, Byron J., Zhu, Yi, Lu, Qun. Rho GTPases as therapeutic targets in Alzheimer’s disease. . December 2017; (): . http://hdl.handle.net/10342/8387. Accessed September 29, 2023.
    Collections
    • Open Access

    xmlui.ArtifactBrowser.ItemViewer.elsevier_entitlement

    East Carolina University has created ScholarShip, a digital archive for the scholarly output of the ECU community.

    • About
    • Contact Us
    • Send Feedback